<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="190636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611351</url>
  </required_header>
  <id_info>
    <org_study_id>122-05</org_study_id>
    <secondary_id>P30CA036727</secondary_id>
    <secondary_id>UNMC-12205</secondary_id>
    <nct_id>NCT00611351</nct_id>
  </id_info>
  <brief_title>Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor bone marrow transplant or peripheral stem cell
      transplant helps stop the growth of cancer cells and helps stop the patient's immune system
      from rejecting the donor's stem cells. When certain stem cells from a donor are infused into
      the patient they may help the patient's bone marrow make stem cells, red blood cells, white
      blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune
      response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after
      the transplant may stop this from happening.

      PURPOSE: This phase II trial is studying how well giving busulfan together with
      cyclophosphamide and antithymocyte globulin followed by donor stem cell transplant works in
      treating patients with hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the incidence of grade II-IV acute graft-versus-host disease in patients
           with hematologic cancer or other diseases treated with a myeloablative conditioning
           regimen comprising targeted (steady-state concentration of 800-1,000 ng/mL) busulfan,
           cyclophosphamide, and anti-thymocyte globulin followed by matched unrelated donor
           allogeneic hematopoietic stem cell transplantation.

        -  To determine the day +100 transplantation-related mortality in these patients.

      Secondary

        -  To determine the effect of cyclophosphamide pharmacokinetic parameters on day +100
           transplantation-related mortality in these patients.

        -  To determine the ability of low-dose anti-thymocyte globulin administered on day +5 to
           induce activation-induced cell death of activated donor lymphocytes.

        -  To determine the incidence of chronic graft-versus-host disease in patients treated
           with this regimen.

        -  To determine event-free and overall survival of patients treated with this regimen.

        -  To evaluate pharmacogenomic associations between genetic polymorphisms in drug
           disposition enzymes with the pharmacokinetics of busulfan and cyclophosphamide.

      OUTLINE:

        -  Myeloablative conditioning regimen: Patients receive busulfan IV over 2 hours on days
           -8 to -5; cyclophosphamide IV over 4 hours on days -3 to -2; and anti-thymocyte
           globulin IV over 6 hours on day -3 and then over 4 hours on days -2, -1, and 5.

        -  Allogeneic hematopoietic stem cell transplantation: Patients undergo allogeneic bone
           marrow or peripheral blood stem cell infusion on day 0.

        -  Graft-versus-host-disease prophylaxis: Patients receive tacrolimus IV continuously or
           orally on days 6 to150, followed by an even taper to day 180 in the absence of
           graft-versus-host-disease. Patients also receive mycophenolate mofetil IV or orally
           beginning on day 6 and continuing to day 28.

      Patients undergo blood collection periodically during study for pharmacokinetic,
      pharmacogenomic, and other translational studies. Genomic DNA extracted from blood samples
      is analyzed by polymerase chain reaction for genetic polymorphisms in
      cyclophosphamide/busulfan disposition enzymes. Activated donor lymphocytes are assessed
      using flow cytometry to measure activation-induced cell death, as reflected by apoptosis in
      activated T cells. Chimerism on or around day 100 is also assessed using fluorescence in
      situ hybridization analysis and DNA fingerprinting.

      After completion of study treatment, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplantation-related mortality at 100 days post-transplantation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade II-IV acute graft-versus-host-disease (GVHD)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Secondary Myelofibrosis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Pathologically confirmed diagnosis of 1 of the following:

               -  Acute myeloid leukemia

               -  Acute lymphocytic leukemia

               -  Chronic myelogenous leukemia beyond first chronic phase (i.e., 2nd chronic
                  phase, accelerated phase, or blast crisis)

               -  Multiple myeloma

               -  Myelodysplastic syndromes

               -  Malignant lymphoma

               -  Myelofibrosis

          -  Requirement for myeloablative conditioning regimen confirmed by attending physician

          -  Available donor must meet the following criteria:

               -  HLA phenotypically identical unrelated donor by low, intermediate, or high
                  resolution for HLA class I antigens, and by high resolution for HLA class II
                  antigens

                    -  Matched at the A, B, and DRβ1 loci

                    -  Single HLA-A or HLA-B antigen mismatch allowed

               -  Meets all National Marrow Donor Program or foreign registry criteria for
                  allogeneic bone marrow/stem cell donors

               -  Peripheral blood stem cells are the preferred product on this study but bone
                  marrow is allowed

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  DLCO ≥ 50% predicted

          -  LVEF ≥ 45%

          -  Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 65 mL/min

          -  Serum total bilirubin ≤ 2.0 mg/dL

          -  No active uncontrolled infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No HIV infection

          -  No chronic active hepatitis B or C or evidence of cirrhosis on liver biopsy

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel Devetten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 3, 2011</lastchanged_date>
  <firstreceived_date>February 7, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Marcel Devetten, M.D.</name_title>
    <organization>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</organization>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>secondary myelofibrosis</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
